SANGAM RAJAK

Dr. SANGAM RAJAK


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Rohit Anthony SinhaRohit Anthony Sinha
Rohit Anthony Sinha
SRSANGAM RAJAK
SANGAM RAJAK
BSBrijesh Kumar Singh
Brijesh Kumar Singh
PYPaul Yen
Paul Yen
Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors which belong to the nuclear hormone receptor superfamily. They regulate key aspects of energy metabolism within cells. Recently, PPARα has been implicated in the regulation of autophagy-lysosomal function, which plays a key role in cellular energy metabolism. PPARα transcriptionally upregulates several genes involved in the autophagy-lysosomal degradative pathway that participates in lipolysis of triglycerides within the hepatocytes. Interestingly, a reciprocal regulation of PPARα nuclear action by autophagy-lysosomal activity also exists with implications in lipid metabolism. This review succinctly discusses the unique relationship between PPARα nuclear action and lysosomal activity and explores its impact on hepatic lipid homeostasis under pathological conditions such as non-alcoholic fatty liver disease (NAFLD).

1 January 2021 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDP. Vineeth Daniel
P. Vineeth Daniel
SDSurbhi Dogra
Surbhi Dogra
PRPriya Rawat
Priya Rawat
ACAbhinav Choubey
Abhinav Choubey
AKAiysha Siddiq Khan
Aiysha Siddiq Khan
PMProsenjit Mondal
Prosenjit Mondal
Overconsumption of sucrose and other sugars has been associated with non-alcoholic fatty liver disease (NAFLD). Reports suggest that hepatic de novo lipogenesis (DNL) is an important contributor to and regulator of carbohydrate-induced hepatic lipid accumulation in NAFLD. The mechanisms responsible for the increase in hepatic DNL due to overconsumption of carbohydrate diet are less than clear; however, literatures suggest high carbohydrate diet to activate the lipogenic transcription factor carbohydrate response element-binding protein (ChREBP), which further transcribes genes involved in DNL. Here we provide an evidence of an unknown link between NF-κB activation and increased DNL. Our data indicates high carbohydrate diet to enforce nuclear shuttling of hepatic NF-κB p65 and repress transcript levels of Sorcin, a cytosolic interacting partner of ChREBP. Reduced sorcin levels, further prompted ChREBP nuclear translocation, leading to enhanced DNL and intrahepatic lipid accumulation both in vivo and in vitro. We further report that pharmacological inhibition of NF-κB, abrogated high carbohydrate diet-mediated sorcin repression, and thereby prevented ChREBP nuclear translocation and this, in turn, attenuated hepatic lipid accumulation both in in vitro and in vivo. Additionally, sorcin knockdown blunted the lipid-lowering ability of the NF-κB inhibitor in vitro. Together, these data suggest a heretofore unknown role for NF-κB in regulating ChREBP nuclear localization, and activation, in response to high carbohydrate diet, for further explorations in lines of NAFLD therapeutics.

28 February 2024 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Verified
Journal Article
Closed access
SRSANGAM RAJAK
SANGAM RAJAK

13 July 2023 in Cells
Verified
Journal Article
Open access
PDF file
ATArchana Tewari
Archana Tewari
SRSANGAM RAJAK
SANGAM RAJAK
SRSana Raza
Sana Raza
PGPratima Gupta
Pratima Gupta
BCBandana Chakravarti
Bandana Chakravarti
Rohit Anthony SinhaRohit Anthony Sinha
Rohit Anthony Sinha
Non-alcoholic steatohepatitis (NASH) is a clinically serious stage of non-alcoholic fatty liver disease (NAFLD). Histologically characterized by hepatocyte ballooning, immune cell infiltration, and fibrosis, NASH, at a molecular level, involves lipid-induced hepatocyte death and cytokine production. Currently, there are very few diagnostic biomarkers available to screen for NASH, and no pharmacological intervention is available for its treatment. In this study, we show that hepatocyte damage induced by lipotoxicity results in the release of extracellular RNAs (eRNAs), which serve as damage-associated molecular patterns (DAMPs) that stimulate the expression of pro-apoptotic and pro-inflammatory cytokines, aggravate inflammation, and lead to cell death in HepG2 cells. Furthermore, the inhibition of eRNA activity by RNase 1 significantly increases cellular viability and reduces NF-kB-mediated cytokine production. Similarly, RNase 1 administration significantly improves hepatic steatosis, inflammatory and injury markers in a murine NASH model. Therefore, this study, for the first time, underscores the therapeutic potential of inhibiting eRNA action as a novel strategy for NASH treatment.

1 November 2020 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
SRSANGAM RAJAK
SANGAM RAJAK
SRSana Raza
Sana Raza
ATArchana Tewari
Archana Tewari
SYShivmurat Yadav
Shivmurat Yadav
SUJOY GHOSHSUJOY GHOSH
SUJOY GHOSH
Rohit Anthony SinhaRohit Anthony Sinha
Rohit Anthony Sinha

20 June 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
ATArchana Tewari
Archana Tewari
SRSANGAM RAJAK
SANGAM RAJAK
SRSana Raza
Sana Raza
PGPratima Gupta
Pratima Gupta
BCBandana Chakravarti
Bandana Chakravarti
Rohit Anthony SinhaRohit Anthony Sinha
Rohit Anthony Sinha
Non-alcoholic steatohepatitis (NASH) is a clinically serious stage of non-alcoholic fatty liver disease (NAFLD). Histologically characterized by hepatocyte ballooning, immune cell infiltration and fibrosis, NASH at a molecular level involves lipid induced hepatocyte death and cytokine production. Currently, there are very few diagnostic biomarkers available to screen NASH, and no pharmacological intervention is available for its treatment. In this study, we show that hepatocyte damage by lipotoxicity results in the release of extracellular RNAs (eRNAs) which serve as damage-associated molecular patterns (DAMPs) that stimulate the expression of pro-apoptotic and pro-inflammatory cytokines, aggravating inflammation, and cell death in HepG2 cells. Furthermore, the inhibition of eRNA activity by RNase 1 significantly increased cellular viability and reduced NF-kB mediated cytokine production. Similarly, RNase 1 administration significantly improved hepatic steatosis, inflammatory and injury markers in a murine NASH model. This study, therefore, for the first time, underscores the therapeutic potential of inhibiting eRNA action as a novel strategy for NASH treatment.